George W. Wright
YOU?
Author Swipe
Gene-regulatory axes of diffuse large B-cell lymphoma subtypes Open
Introduction: Diffuse large B-cell lymphoma (DLBCL) is stratified into genetic subtypes (MCD, BN2, A53, N1, EZB, ST2) that differ in their gene expression profiles, oncogenic mechanisms, and response to therapy. Using paired single cell RN…
View article: Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma
Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma Open
Although follicular lymphoma (FL) typically follows an indolent course, patients with FL who experience early events, such as transformation or progression, have increased risk of death related to lymphoma. The FL24Cx is an algorithm based…
View article: High-grade B-cell lymphoma, not otherwise specified: an LLMPP study
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study Open
Molecular characterization of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS), is hindered by its rarity, evolving definition, and poor diagnostic reproducibility. To address this challenge, we analyzed 92 HGBCL-NOS tumors …
View article: Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes
Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes Open
Diffuse large B-cell lymphomas (DLBCL) are genetically and clinically heterogenous. Despite advances in the gene-expression and genomic characterization, the pathophysiology of high-risk DLBCL still remains incompletely understood. We repo…
Genetic Subclones Reveal Phenotypic Heterogeneity in Diffuse Large B-Cell Lymphoma Open
Introduction Genetic and gene expression subtypes of diffuse large B-cell lymphoma (DLBCL) capture biological differences between tumors that influence the response to immunochemotherapy. Single cell analysis of DLBCL could illuminate furt…
View article: Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas Open
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normal…
Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas Open
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The rol…
Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas Open
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normal…
Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas Open
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The rol…
View article: Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Inhibition of neddylation increases expression of BCR subunits
View article: Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Mutation of CD79A and CD79B glycosylated residues does not alter sensitivity to MMAE
View article: Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
CRISPR Screen Scores
View article: Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
KLHL6 loss does not score as a negative regulator of surface CD79B or Pola-V sensitivity in CRISPR screens of ABC DLBCL cell lines and KLHL6 loss does not sensitize to MMAE
View article: Supplementary Figure S2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knockout of SLC35A1, SLC35A2, and ST6GAL1 decreases surface a2,6-linked sialic acid.
View article: Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Mutation of CD79A and CD79B glycosylated residues does not alter sensitivity to MMAE
View article: Supplementary Table 3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
KLHL6 proteomics
View article: Supplementary Table 2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Glycoproteomics
View article: Supplementary Figure S13 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S13 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
DLBCL mutations targeting the CD79B intracellular domain and their effect on surface BCR levels
View article: Supplementary Figure S4 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S4 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
SLC35A2 targeted degradation by dTag modification synergizes with Pola-V.
View article: Supplementary Figure S11 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S11 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knockout of the E3 ligase KLHL6 results in increased cell surface CD79B in a human model of GCB DLBCL
View article: Supplementary Figure S5 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S5 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
CD79B immunohistochemistry is not predictive of Pola-V sensitivity
View article: Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
CRISPR Screen Scores
View article: Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Inhibition of neddylation increases expression of BCR subunits
Supplementary Figure S11 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knockout of the E3 ligase KLHL6 results in increased cell surface CD79B in a human model of GCB DLBCL
Supplementary Figure S6 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Sialidase treatment reduces surface α2,6-linked sialic acid
Supplementary Figure S3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Small-molecule sialyltransferase inhibition synergizes with Pola-V in ABC and GCB DLBCL
Supplementary Figure S12 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knockout of Klhl6 in mouse germinal center B cells increases surface BCR expression
Supplementary Figure S4 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
SLC35A2 targeted degradation by dTag modification synergizes with Pola-V.
Supplementary Figure S8 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knock-In mutations to specific N-linked glycosylation sites results in higher CD79B but not immunoglobulin MFI by flow cytometry